secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001193805-24-001316
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic Q3 net loss $24.4M; positive ENSURE futility analysis; cash runway into Q3 2025
--------------------------------------------------------------------------------

- Net loss Q3 2024: $24.4M ($0.24/share) vs $22.8M ($0.51/share) in Q3 2023.
- Cash $59.1M as of Sep 30, 2024; expected to fund operations into Q3 2025.
- Phase 3 ENSURE futility analysis positive: IDMC recommends continuation without sample size increase.
- Top-line data from Phase 2 CALLIPER (PMS) expected April 2025; ENSURE-1 completion Q2 2026.
- New leadership: Jason Tardio appointed COO/President; Werner Gladdines promoted to CDO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524001316/0001193805-24-001316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524001316/e663991_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-001316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer